What investigation/therapy would you suggest next?
1.
Refer for echo optimization of AV and VV delays 2.
Refer for premature ventricular contraction (PVC) ablation
3.
Increase LV pacing output
4.
Refer for lead repositioning 5. Increase diuretics
Check full blood count
Answer ECG ( Fig 1A) demonstrates biventricular pacing whilst ( Fig 1B) demonstrates a change in morphology consistent with lone RV pacing. A pacing check confirmed there was no LV capture at maximum output. (Fig 1C) shows that the LV lead has been withdrawn out of the vascular system entirely and is curled up around the generator. The patient was therefore admitted for repositioning of the LV lead. Whilst other factors such as suboptimal medical therapy, anaemia, suboptimal AV timing and arrhythmias may all contribute to non-response, they will not be the main factor on this occasion. Whilst the non-response here is due to a lack of LV capture, this is due to gross lead displacement and therefore will not be improved by increasing LV output. It is worth noting, however, that the patient does have a high PVC burden on both ECGs, which will both decrease the effective bi-ventricular pacing percentage, and indeed may have contributed to the aetiology of the LV impairment. If the patient remains symptomatic despite lead repositioning, a trial of amiodarone to suppress the ectopy or referral for PVC ablation may be advised (see 'Discussion' below).
The most likely explanation for the lead displacement is 'Twiddler's Syndrome'. First described in 1968, this refers to malfunction of a pacemaker due to the patient's deliberate or subconscious manipulation of the pulse generator (1). Elderly and obese patients appear to be at increased risk because the presence of loose subcutaneous tissue allows for easier rotation (2) . Creating a small pocket, suturing the device to the fascia or use of a Dacron pouch can help minimise this.
Discussion
Around one third of patients currently do not respond to CRT based on the current guidelines, and more than 40% do not show a LV reverse modelling response. In some of these cases, this could be improved with better benefit from echo-guided or device-guided AV-optimization compared to the empiric settings; however, patients with prolonged AV-conduction were not included in this prospective, randomized study (7) . Other data suggest patients with prolonged AV-interval to derive benefit from AV-delay optimization (8) .
Additional assessment includes measurement of LV interventricular and intraventricular mechanical dyssynchrony. Interventricular mechanical dyssynchrony is measured as the difference of the aortic and pulmonary pre-ejection interval and its immediate decrease shows effective resynchronization. Intraventricular dyssynchrony can be evaluated by tissue Doppler imaging or by strain dyssynchrony based on speckle tracking.
VV-optimization is a useful tool to correct intraventricular dyssynchrony, and is usually achieved through optimising LV stroke volume. It is also important to ascertain whether the patient is in normal SR or AF. AF may lead to tachycardia with loss of LV pacing or fusion/pseudofusion beats with ineffective resynchronization. It is vital to control the ventricular rate, with AV node ablation necessary if medication is inadequate. The role of pulmonary vein isolation in such patients is currently unclear and the subject of ongoing trials. Frequent PVCs, more often observed in patients with ischaemic cardiomyopathy, may also cause non-response, and require treatment with antiarrhythmics, or consideration of PVC ablation. Interrogation of the device will demonstrate the AF or PVC burden; Bi-V pacing percentage must be higher than 90% to ensure optimal CRT. However, fusion and pseudofusion may not be detected by the device, and so the reported Bi-V pacing percentage may be falsely high.
Finally, it is important not to forget to examine comorbidities such as diabetes, ischaemic heart disease, and vascular and cerebral diseases, which carry an increased risk of pool renal function, anaemia and hypotension, which are in turn associated with poor prognosis in CRT recipients. Optimal treatment of these factors may improve CRT response. Non-responders may be on inadequate medical therapy for their HF. Medications may be discontinued as HF worsens or if they develop renal dysfunction, and it is also importance to check for patient compliance for prescribed medications.
